More than 500 members of the myasthenia gravis (MG) community are expected at a conference featuring strategies for patient education, advances in science and treatment, and discussions on managing MG. The Myasthenia Gravis Foundation of America (MGFA)’s National Patient Conference, being held March 30-April 1 in Phoenix and virtually, is…
One year of treatment with inebilizumab eased symptoms and improved daily functioning for people with generalized myasthenia gravis (gMG) positive for antibodies against the acetylcholine receptor (AChR), according to new data from the Phase 3 MINT clinical trial. Amgen, the company developing inebilizumab, will present the new…
Repeated cycles of Rystiggo (rozanolixizumab-noli) do not increase the risk of safety problems in people with generalized myasthenia gravis (gMG), according to a new analysis of clinical trial data. “These results showed that treatment with [Rystiggo] in patients with gMG was well tolerated and that the incidence of…
Rituximab can safely and effectively control myasthenia gravis (MG) in patients with antibodies against muscle-specific kinase or MuSK, according to a new analysis. “Rituximab has demonstrated effectiveness and safety as a treatment for anti-MuSK MG. It has the potential to help patients with any baseline severity, especially those…
Tofacitinib, an approved medication for some types of inflammatory arthritis and inflammatory bowel disease, may also help treat myasthenia gravis (MG), a new study done in an animal model and cell samples suggests. Treatment with tofacitinib was found to ease muscle weakness and weight loss in a rat model…
Top-line results from a Phase 3 clinical trial of batoclimab in people with generalized myasthenia gravis (gMG) are expected by the end of March, Roivant, which is developing the antibody therapy through its subsidiary Immunovant, reported. The company said that trial findings will inform further decisions regarding next…
Nipocalimab outperformed a placebo at easing the severity of generalized myasthenia gravis (gMG) in a Phase 3 clinical trial called Vivacity-MG3. Full results from the trial were detailed in the study, “Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3,…
Treatment with ARGX-119, an experimental therapy being developed by Argenx, led to improvements in muscle strength and survival in a mouse model of myasthenia gravis (MG) driven by self-reactive antibodies that target the muscle-specific kinase (MuSK) protein, a study shows. While the findings indicated ARGX-119 may ease…
Throughout 2024, the team at Myasthenia Gravis News has brought you the latest updates on research advances and treatment options for myasthenia gravis (MG). We look forward to continuing to serve the MG community in the years to come. Here, we’ve compiled a list of the 10 most-read articles…
People with myasthenia gravis (MG) who experience exacerbations tend to require longer and more frequent hospital stays, according to a recent study. Findings from the study, which analyzed data from a U.S. Veterans Affairs (VA) healthcare database, also suggest the risk of exacerbations is higher in people with MG…
Get regular updates to your inbox.
